German construction sector still in recession, civil engineering only bright spot
LOUISVILLE, Colo. - Charlotte’s Web Holdings, Inc. (TSX:CWEB) (OTCQB:CWBHF), a CBD wellness company with a market capitalization of $16.14 million and annual revenue of $50.32 million, announced Thursday plans to develop a Scientific Advisory Board to guide its medical strategy and research initiatives, with work expected to begin this month. According to InvestingPro analysis, the company maintains a healthy gross profit margin of 47.67% despite challenging market conditions.
The hemp-derived CBD wellness company said the board will shape its research agenda, clinical initiatives, and help translate botanical science into patient-centered solutions. While the company’s current InvestingPro Financial Health score stands at Fair, with a strong current ratio of 3.83 indicating solid short-term liquidity, analysts note several additional financial metrics available for deeper analysis through the Pro Research Report.
Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte’s Web, will lead the board’s development. Bonn-Miller is a cannabinoid researcher with over 20 years of experience who has published approximately 200 research papers.
"The establishment of our Scientific Advisory Board is a critical step in advancing the clinical relevance of hemp-based therapeutics," said Bonn-Miller in the press release.
As part of its medical channel strategy, the company plans to create Continuing Medical Education content for healthcare professionals to address what it describes as a gap in patient care for conditions like pain, anxiety, and sleep issues.
The initiative will also support Charlotte’s Web’s partnership with DeFloria, Inc. and Ajna BioSciences PBC, which is developing a full-spectrum CBD hemp extract (AJA001) as a treatment for irritability associated with autism spectrum disorder. This candidate has received FDA approval to proceed with planned Phase 2 clinical trials.
Charlotte’s Web, founded over a decade ago, is known for its work with Charlotte Figi, which helped establish the hemp wellness category. The company maintains a vertically integrated business model with testing from "soil to shelf" for quality assurance.
The company’s product line includes CBD oil tinctures, gummies, capsules, topical creams, and pet products distributed to retailers and healthcare practitioners throughout the U.S. For investors seeking comprehensive analysis of Charlotte’s Web Holdings and similar companies in the CBD sector, InvestingPro offers detailed financial health assessments, fair value estimates, and expert insights through its extensive Pro Research Reports covering over 1,400 US equities.
In other recent news, Charlotte’s Web Holdings Inc. reported its second-quarter 2025 earnings, revealing a mixed financial outcome. The company missed earnings per share (EPS) forecasts, posting an actual EPS of -$0.04 compared to the expected -$0.03. However, Charlotte’s Web exceeded revenue expectations, reporting $12.8 million, which was a 15.73% increase over the forecasted $11.06 million. This revenue beat highlights a positive aspect of the company’s financial performance. Despite these mixed results, the stock price remained stable, reflecting cautious investor sentiment. These developments offer investors insight into the company’s current financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.